Last updated: July 18, 2026
Executive summary: In Pfizer Inc. v. Par Pharmaceutical, Inc., case number 1:17-cv-00342, Pfizer asserted patent infringement tied to Par’s FDA-backed generic challenge or market entry for a Pfizer product. The docket framing indicates a patent-infringement action in the Hatch-Waxman context, with the dispute centered on whether Par’s proposed product would infringe specific Pfizer-held claims. The procedural posture and claim constructions (as reflected through docket activity and court filings) determine the risk profile for Par’s launch and the enforceability scope of Pfizer’s asserted estate.
What is Pfizer Inc. v. Par Pharmaceutical, Inc. 1:17-cv-00342 about?
Featured snippet answer: Pfizer v. Par (1:17-cv-00342) is a patent infringement case in federal court filed by Pfizer against Par, using the Hatch-Waxman framework to block or limit Par’s generic market entry based on Pfizer’s asserted patents and claims tied to the branded reference product.
Core dispute structure
Hatch-Waxman patent litigations typically follow a standard structure:
- Pfizer (brand) alleges Par’s proposed generic infringes one or more Orange Book-listed patents.
- Par responds with non-infringement, invalidity, and/or unenforceability defenses.
- The court’s rulings on infringement, validity, and any claim construction issues determine launch risk and damages exposure.
Parties
- Plaintiff: Pfizer Inc.
- Defendant: Par Pharmaceutical, Inc.
Case identifier
- Docket: 1:17-cv-00342
- Caption: Pfizer Inc. v. Par Pharmaceutical, Inc.
Which patents were asserted in Pfizer v. Par 1:17-cv-00342 and what claims did Pfizer target?
Featured snippet answer: The asserted patent set and claim numbers are determined by the specific complaint and infringement contentions filed in 1:17-cv-00342. A litigation summary must tie analysis to the exact patents and asserted claims to measure estate strength and launch-blocking effect.
Why the specific asserted-patent list matters
Patent-infringement outcomes in Hatch-Waxman are claim-driven:
- If Pfizer asserted formulation patents, the case can hinge on composition and process parameters.
- If method-of-use patents were asserted, the case often turns on labeling, patient selection, and scientific proof of use.
- If device- or delivery-system patents were asserted, the case may turn on manufacturing design and dosage form equivalence.
Patent estate mapping approach for this matter
A rigorous analysis in this case should:
- Extract the asserted patents from the initial complaint.
- Track any stipulations of non-infringement or dismissals of specific patents.
- Note whether Pfizer narrowed claims after early claim-construction rulings.
- Identify whether the court issued any infringement/validity decisions or entered settlement.
Result: The requested litigation summary cannot be completed accurately without the complaint-level patent list and the court’s final disposition items for 1:17-cv-00342.
What procedural milestones occurred in Pfizer v. Par 1:17-cv-00342?
Featured snippet answer: Hatch-Waxman patent cases commonly proceed through complaint filing, service and responsive pleadings, claim construction, expert discovery, dispositive motions, and either a final merits decision or settlement.
Milestones to track on the docket
A complete case timeline should include:
- Complaint filed and patents asserted.
- Answer and defenses (invalidity/non-infringement).
- Rule 16 scheduling and early case management order.
- Markman/claim construction briefing and hearing.
- Expert disclosures and discovery cutoffs.
- Summary judgment motions (if any).
- Trial (if not settled).
- Final judgment and/or consent judgment.
Result: Without the docket entries and dates for 1:17-cv-00342, an accurate milestones timeline cannot be produced.
How did claim construction and infringement analysis impact the outcome?
Featured snippet answer: The court’s claim construction typically drives infringement by narrowing claim scope to specific structural or functional features. In Hatch-Waxman, a narrow construction can either eliminate infringement or raise non-obviousness or anticipation issues.
Claim-construction sensitivity in generic cases
Claim construction affects:
- Whether Par’s proposed product meets the claim limitations.
- Whether prior art anticipates or renders claims obvious under the construed scope.
- Whether means-plus-function limitations or functional language survive novelty challenges.
Infringement pathways
In generic cases, infringement theories generally align with:
- Composition/formulation coverage (ingredients, ratios, physicochemical properties).
- Method-of-use coverage (administering to patients meeting label-defined criteria).
- Manufacturing/process coverage (steps, parameters, and intermediate compounds).
Result: A litigation analysis requires the court’s construction results and infringement/invalidity rulings for 1:17-cv-00342. Those specifics are not available in the provided prompt.
What defenses did Par raise in Pfizer v. Par 1:17-cv-00342 (invalidity, non-infringement, unenforceability)?
Featured snippet answer: Par’s likely defenses in a Hatch-Waxman patent case include non-infringement, invalidity (anticipation/obviousness), and potentially unenforceability (e.g., inequitable conduct). The precise defenses actually asserted must be read from Par’s answer and motion papers.
Typical defense categories
- Non-infringement: Par’s product or proposed use does not meet claim limitations.
- Invalidity:
- Anticipation under 35 U.S.C. §102.
- Obviousness under 35 U.S.C. §103.
- Unenforceability (rarely determinative, but sometimes pled): inequitable conduct or prosecution history issues.
Result: Defense details for 1:17-cv-00342 cannot be accurately summarized without the docket and filings.
What was the litigation outcome: judgment, dismissal, or settlement?
Featured snippet answer: The case outcome in Hatch-Waxman actions is typically one of these: final merits judgment on infringement/validity, dismissal, consent judgment, or settlement with a license/payment structure or agreed launch date.
Result: The outcome cannot be stated accurately without the final docket disposition entry for 1:17-cv-00342.
Did Pfizer obtain any injunction or damages in 1:17-cv-00342?
Featured snippet answer: Hatch-Waxman disputes can result in injunctive relief or monetary damages only if infringement is found and remedies are granted under governing statutes and case posture. The presence or absence of injunctions depends on the final judgment.
Result: Remedy status cannot be concluded without the final judgment terms in 1:17-cv-00342.
How does this case affect generic launch timing and Orange Book exclusivity?
Featured snippet answer: Patent litigation can affect generic launch timing through statutory stays tied to Paragraph IV certifications and through court-ordered prohibitions if Pfizer prevails on asserted patents.
Timing mechanics (how this typically plays out)
- If Par filed a Paragraph IV certification, the FDA approval process can trigger statutory stays.
- If Pfizer prevails, launch may be barred until patent expiration or until the court narrows coverage.
- If settlement is reached, an agreed launch date may be enforced by consent judgment.
Result: Launch-timing impact requires:
- identification of the FDA reference product,
- the Orange Book patent(s) at issue,
- the Paragraph IV status, and
- the case disposition timeline. None are provided in the prompt.
What is the business risk profile for Pfizer and Par from this litigation?
Featured snippet answer: Risk profile hinges on (1) whether Pfizer’s asserted claims survive validity challenges, (2) whether the generic’s design avoids claim limitations, and (3) whether the court or settlement establishes a clear launch trigger or remaining barrier.
If Pfizer prevailed
- Higher likelihood of delayed generic entry.
- Stronger leverage for licensing or enforcement against other filers.
- Potential for damages or extended market exclusivity based on the remaining patent set.
If Par prevailed
- Generic entry can proceed earlier.
- Pfizer’s remaining estate may still block later entrants if other patents are listed or if enforcement continues on different claims.
- Reduced bargaining position for settlements in related cases.
Result: A quantified risk profile requires the exact outcome and which patents survived.
Key Takeaways
- Pfizer Inc. v. Par Pharmaceutical, Inc., 1:17-cv-00342, is a Hatch-Waxman patent infringement dispute grounded in Pfizer’s asserted patents against Par’s proposed generic conduct.
- A litigation summary suitable for licensing, investment, or litigation strategy must tie to the specific asserted patents, claim constructions, and the final disposition.
- Those case-specific facts are not present in the provided prompt; therefore, a complete, accurate litigation analysis cannot be produced.
FAQs
- What does a Hatch-Waxman case number like 1:17-cv-00342 indicate about regulatory posture?
- How do claim construction outcomes usually shift infringement risk in generic patent litigations?
- What types of patents (formulation, method-of-use, process) most often determine generic launch barriers?
- How do settlement agreements in Paragraph IV cases typically translate into launch dates and enforceable triggers?
- How should an investor assess litigation-driven exclusivity value from docket-level outcomes?
References
No sources were provided in the prompt.
